 |
|
Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Kuei-Chuan Lee, Pei-Shan Wu, Han-Chieh Lin
Clin Mol Hepatol. 2023;29(1):77-98. Published online 2022 Oct 13 DOI: https://doi.org/10.3350/cmh.2022.0237
|
|
Citations to this article as recorded by
 Neuregulin 4 as a novel adipokine in energy metabolism
Yuanbin Liu, Mingkai Chen
Frontiers in Physiology.2023;[Epub] CrossRef Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
Seogsong Jeong, Woo-Young Shin, Yun Hwan Oh
Frontiers in Endocrinology.2023;[Epub] CrossRef A Combination of an Angiotensin II Receptor and a Neprilysin Inhibitor Attenuates Liver Fibrosis by Preventing Hepatic Stellate Cell Activation
Junya Suzuki, Kosuke Kaji, Norihisa Nishimura, Takahiro Kubo, Fumimasa Tomooka, Akihiko Shibamoto, Satoshi Iwai, Yuki Tsuji, Yukihisa Fujinaga, Koh Kitagawa, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji
Biomedicines.2023; 11(5): 1295. CrossRef
|